Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy/Potency of a Single Dose of Xisomab 3G3, Administered at the Beginning of a Regular Hemodialysis Procedure, in Patients With End-Stage Renal Disease on Chronic Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Xisomab 3G3 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Aronora
- 19 Jul 2021 According to an Aronora media release, data from this trial will be presented at the XXIX Congress of the International Society on Thrombosis and Haemostasias (ISTH)
- 19 Jul 2021 Top-line Results published in an Aronora Media Release.
- 04 Jun 2021 Results published in the Blood